Chikungunya as a paradigm for emerging viral diseases: Evaluating disease impact and hurdles to vaccine development

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
dengue fever 1 infectiousdiseases
infectious disease 2 infectiousdiseases
measles 5 infectiousdiseases
yellow fever 1 infectiousdiseases
Venezuelan equine encephalitis 1 infectiousdiseases
chikungunya 11 infectiousdiseases

There are not enough annotations found in this document to create the proximity graph.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Select Disease Character Offset Disease Term Instance
Venezuelan equine encephalitis 13698 among those who had been previously vaccinated with other live-attenuated alphavirus vaccines (i.e., Venezuelan equine encephalitis virus), suggesting immunological interference [[35]]. Ultimately, development of this live-attenuated
chikungunya 2312 by A. albopictus mosquitoes. Infection with CHIKV typically causes a self-limiting febrile illness, chikungunya fever (CHIKF), characterized by chronic, severe joint pain, and sometimes accompanied by an itchy maculo-papular
chikungunya 4858 1,500,000 cases of CHIKF were reported (http://www.who.int/denguecontrol/arbo-viral/other_arboviral_ chikungunya /en/). Furthermore, the global impact of CHIKV is constantly growing, due to the introduction and spread
chikungunya 5733 transmission have been identified.Data from World Health Organization (http://www.who.int/emergencies/diseases/ chikungunya /en/) and Pan American Health Organization (https://www.paho.org/hq/index.php?option=com_topics&view=article&id=343&Itemid=40931&lang=en).
chikungunya 5890 (https://www.paho.org/hq/index.php?option=com_topics&view=article&id=343&Itemid=40931&lang=en). CHIKV, chikungunya virus.Secondly, although the case–fatality rate of CHIKF is relatively low—usually well below 1%
chikungunya 17315 and efficacy in mice, NHPs)[[41]–[43]]EILV/CHIKVUniversity of Texas Medical BranchRecombinant Eilat/ chikungunya chimeric virus that is replication-defective in vertebrate cells1Late preclinical (immunogenicity and
chikungunya 17480 vertebrate cells1Late preclinical (immunogenicity and efficacy in mice, NHPs)[[48]]Abbreviations: CHIKF, chikungunya fever; CHIKV, chikungunya virus; EILV, Eilat virus; NHP, nonhuman primate; nsP3, nonstructural protein
chikungunya 17506 preclinical (immunogenicity and efficacy in mice, NHPs)[[48]]Abbreviations: CHIKF, chikungunya fever; CHIKV, chikungunya virus; EILV, Eilat virus; NHP, nonhuman primate; nsP3, nonstructural protein 3.Viral-vectored vaccinesA
chikungunya 20874 identification of a suitable site with adequate incidence of CHIKF to demonstrate efficacy.Bottlenecks for chikungunya vaccine development: Which obstacles should be removed?CHIKF outbreak control is hampered by the lack
chikungunya 28974 five papersVenturi G, Di Luca M, Fortuna C, Remoli ME, Riccardo F, Severini F, et al. Detection of a chikungunya outbreak in Central Italy, August to September 2017. Euro Surveill. 2017;22(39). doi: 10.2807/1560-7917.ES.2017.22.39.17-00646.
chikungunya 29326 RJ, Thomas SJ, et al. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. The
chikungunya 29646 25739878.Chang LJ, Dowd KA, Mendoza FH, Saunders JG, Sitar S, Plummer SH, et al. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet. 2014. Epub 2014/08/19.
dengue fever 23901 opportunities to perform efficacy trials in regions endemic for CHIKF, but the typical misdiagnosis of CHIKF as dengue fever [[56]] will need to be overcome with improved surveillance and diagnostics to identify such opportunities.
infectious disease 740 (epub): 1/2019Publication date (collection): 1/2019AbstractChikungunya fever (CHIKF) is an emerging infectious disease caused by an alphavirus transmitted by Aedes spp. mosquitoes. Because mosquito control programs are
infectious disease 29445 vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. The Lancet infectious disease s. 2015. Epub 2015/03/06. doi: 10.1016/S1473-3099(15)70043-5. PubMed PMID: 25739878.Chang LJ, Dowd KA,
measles 16346 NCT01489358, NCT03483961)[[49], [50]]MV-CHIKInst. Pasteur, Themis BioscienceRecombinant live- attenuated measles vaccine expressing CHIKV virus-like particles derived from the structural protein genes2Phase 2 (NCT03101111,
measles 17701 3.Viral-vectored vaccinesA CHIKF vaccine in advanced stages of clinical development employs an attenuated measles virus strain as a vector to express the CHIKV structural proteins [[44]]. In a Phase 1 trial, this vaccine
measles 18084 high-dose. A booster raised seroconversion to 100%, and immunogenicity was not affected by preexisting anti- measles immunity. This vaccine is now in Phase 2 trials (Table 1).Another unique viral-vectored vaccine, EILV/CHIKV,
measles 22726 long-term protection in endemic locations. Viral-vectored platforms such as vesicular stomatitis or measles can also be rapidly adapted for new viral targets and may offer more rapid and durable immunity.Another
measles 29306 C, Mullner M, Putnak RJ, Thomas SJ, et al. Immunogenicity, safety, and tolerability of a recombinant measles -virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator,
yellow fever 7286 long-term manifestations of CHIKF. Unlike other mosquito-borne viruses such as dengue, Zika, and even yellow fever , CHIKV typically causes symptomatic infection, and consequently outbreaks are accompanied by high attack

You must be authorized to submit a review.